Neurocrine appoints Christine Poon to board; bylaws amended to increase board to 10

NEUROCRINE BIOSCIENCES INC

Christine A. Poon appointed as Class I director effective July 11, 2023, term until 2024 annual meeting.
Poon receives $60k annual cash retainer and option for 16,375 shares (~$800k Black-Scholes) vesting over 3 years.
Board size increased from 9 to 10 via amendment to Section 3.2 of Bylaws.
Poon previously served as Vice Chairman of Johnson & Johnson and Dean at Ohio State Fisher College of Business.

item 5.02 item 5.03 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Christine A. Poon

Director

NBIX · NEUROCRINE BIOSCIENCES INC

Effective: 2023-07-11
Filed: July 12, 2023, 7:59 PM ET

On July 11, 2023, the Board of Directors (the “Board”) of Neurocrine Biosciences, Inc., a Delaware corporation (“Neurocrine”), upon the recommendation of its Nominating / Corporate Governance Committee, appointed Christine A. Poon as a member of the Board, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Christine A. Poon was appointed as Director at NEUROCRINE BIOSCIENCES INC.

Action: appointed
Role: Director

Exact text from the filing

On July 11, 2023, the Board of Directors (the “Board”) of Neurocrine Biosciences, Inc., a Delaware corporation (“Neurocrine”), upon the recommendation of its Nominating / Corporate Governance Committee, appointed Christine A. Poon as a member of the Board, effective immediately.

View on SEC.gov

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

NEUROCRINE BIOSCIENCES INC: Amended Section 3.2 of Bylaws to increase board size from nine to ten members (effective 2023-07-11).

Change: bylaw amendment
Effective: 2023-07-11

Exact text from the filing

On July 11, 2023, the Board amended Section 3.2 of Neurocrine’s Bylaws, as amended and restated (the “Bylaws”), to provide that the Board shall consist of ten members.

View on SEC.gov

71 governance changes filed in the last 30 days. Browse all governance changes →

NEUROCRINE BIOSCIENCES INC filing history →

Source: SEC EDGAR

accession 0000914475-23-000047

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.